File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis

TitleA placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis
Authors
KeywordsRofecoxib
Cox-2
Ra
Nsaid
Naproxen
Issue Date2002
PublisherInforma Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/03009742.asp
Citation
Scandinavian Journal of Rheumatology, 2002, v. 31 n. 4, p. 230-238 How to Cite?
AbstractObjective : To evaluate the efficacy and tolerability of rofecoxib 25 mg and 50 mg once daily versus placebo and naproxen 500 mg twice daily in patients with RA. Methods : Eligible patients were randomized (double-blind) to placebo (n = 289), rofecoxib 25 mg (n = 306), 50 mg (n = 286) once daily, or naproxen (n = 142) for 12 weeks. Efficacy assessments included the ACR core set, with prespecified primary endpoints: patient and investigator global assessments of disease activity, tender and swollen joint counts. Investigator-reported adverse experiences, routine laboratory and vital sign measurements were monitored. Results : Rofecoxib 25 mg, 50 mg, and naproxen provided similar treatment effects, significantly different from placebo, consistent with improvement, for all primary endpoints. Effects were evident at the earliest assessment (week 2) and sustained for 12 weeks. All treatments were generally well-tolerated. Conclusions : Rofecoxib 25 mg once daily had similar efficacy to naproxen 500 mg twice daily (a standard dose). No additional benefit was seen with 50 mg rofecoxib.
Persistent Identifierhttp://hdl.handle.net/10722/222202
ISSN
2015 Impact Factor: 2.307
2015 SCImago Journal Rankings: 1.125

 

DC FieldValueLanguage
dc.contributor.authorGeusens, PP-
dc.contributor.authorTruitt, K-
dc.contributor.authorSfikakis, P-
dc.contributor.authorZhao, PL-
dc.contributor.authorDeTora, L-
dc.contributor.authorShingo, S-
dc.contributor.authorLau, CS-
dc.contributor.authorKalla, A-
dc.contributor.authorTate, G-
dc.date.accessioned2016-01-04T07:39:27Z-
dc.date.available2016-01-04T07:39:27Z-
dc.date.issued2002-
dc.identifier.citationScandinavian Journal of Rheumatology, 2002, v. 31 n. 4, p. 230-238-
dc.identifier.issn0300-9742-
dc.identifier.urihttp://hdl.handle.net/10722/222202-
dc.description.abstractObjective : To evaluate the efficacy and tolerability of rofecoxib 25 mg and 50 mg once daily versus placebo and naproxen 500 mg twice daily in patients with RA. Methods : Eligible patients were randomized (double-blind) to placebo (n = 289), rofecoxib 25 mg (n = 306), 50 mg (n = 286) once daily, or naproxen (n = 142) for 12 weeks. Efficacy assessments included the ACR core set, with prespecified primary endpoints: patient and investigator global assessments of disease activity, tender and swollen joint counts. Investigator-reported adverse experiences, routine laboratory and vital sign measurements were monitored. Results : Rofecoxib 25 mg, 50 mg, and naproxen provided similar treatment effects, significantly different from placebo, consistent with improvement, for all primary endpoints. Effects were evident at the earliest assessment (week 2) and sustained for 12 weeks. All treatments were generally well-tolerated. Conclusions : Rofecoxib 25 mg once daily had similar efficacy to naproxen 500 mg twice daily (a standard dose). No additional benefit was seen with 50 mg rofecoxib.-
dc.languageeng-
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.tandf.co.uk/journals/titles/03009742.asp-
dc.relation.ispartofScandinavian Journal of Rheumatology-
dc.rightsScandinavian Journal of Rheumatology. Copyright © Informa Healthcare.-
dc.subjectRofecoxib-
dc.subjectCox-2-
dc.subjectRa-
dc.subjectNsaid-
dc.subjectNaproxen-
dc.titleA placebo and active comparator-controlled trial of rofecoxib for the treatment of rheumatoid arthritis-
dc.typeArticle-
dc.identifier.emailLau, CS: cslau@hku.hk-
dc.identifier.authorityLau, CS=rp01348-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1080/030097402320318431-
dc.identifier.pmid12369656-
dc.identifier.scopuseid_2-s2.0-0036351504-
dc.identifier.hkuros84504-
dc.identifier.volume31-
dc.identifier.issue4-
dc.identifier.spage230-
dc.identifier.epage238-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats